Current Oncology Reports

, Volume 4, Issue 5, pp 415–423

Changing role and decreasing size: Current trends in radiotherapy for hodgkin’s disease

  • Joachim Yahalom
Article

Abstract

Radiotherapy, the first cancer treatment modality that offered cure, is still considered to be the most effective “single agent” in treating Hodgkin’s disease (HD). Yet, the role of radiotherapy in HD has changed dramatically with the advent of effective combination chemotherapy and the rising concern of long-term complications associated with successful treatment of HD. The new principles of integrating radiotherapy into a combined-modality regimen for HD at different prognostic stages are reviewed here, along with the effect of this new role on radiation field size and design.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Peters M: A study in survivals in Hodgkin’s disease treated radiologically. Am J Roentgenol 1950, 63:299–311.Google Scholar
  2. 2.
    Pusey W: Cases of sarcoma and of Hodgkin’s disease treated by exposures to X-rays: a preliminary report. JAMA 1902, 38:166–169.Google Scholar
  3. 3.
    Senn N: Therapeutical value of rontgen ray in treatment of pseudoleukemia. New York Med J 1903, 77:665–668.Google Scholar
  4. 4.
    Gilbert R: La roentgentherapie de la granulomatose maligne. J Radiol Electrol 1925, 9:509–514.Google Scholar
  5. 5.
    Gilbert R: Radiotherapy in Hodgkin’s disease (malignant granulomatosis): anatomic and clinical foundations, governing principles, results. Am J Roentgenol 1939, 41:198–241.Google Scholar
  6. 6.
    Peters M, Middlemiss K: A study of Hodgkin’s disease treated by irradiation. Am J Roentgenol 1958, 79:114–121.Google Scholar
  7. 7.
    Kaplan H: The radical radiotherapy of Hodgkin’s disease. Radiology 1962, 78:553–561.PubMedGoogle Scholar
  8. 8.
    Kaplan HS: Clinical evaluation and radiotherapeutic management of Hodgkin’s disease and the malignant lymphomas. N Engl J Med 1968, 278:892–899.PubMedCrossRefGoogle Scholar
  9. 9.
    Kaplan HS: Radiotherapy of advanced Hodgkin’s disease with curative intent. JAMA 1973, 223:50–53.PubMedCrossRefGoogle Scholar
  10. 10.
    DeVita V, Serpick A, Carbone P: Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 1970, 73:881–895.PubMedGoogle Scholar
  11. 11.
    DeVita VT, Jr., Canellos GP, Moxley JHd: A decade of combination chemotherapy of advanced Hodgkin’s disease. Cancer 1972, 30:1495–1504.PubMedCrossRefGoogle Scholar
  12. 12.
    Rosenberg SA: The management of Hodgkin’s disease: half a century of change. The Kaplan Memorial Lecture. Ann Oncol 1996, 7:555–560.PubMedGoogle Scholar
  13. 13.
    DeVita VT: Hodgkin’s disease. Lancet 1971, 2:46–47.PubMedCrossRefGoogle Scholar
  14. 14.
    Yahalom J: Radiation therapy for Hodgkin’s disease. In Malignant Lymphomas. Edited by Grossbard ML. New York: BC Deecker; 2002:428–441.Google Scholar
  15. 15.
    Backstrand KH, Ng AK, Takvorian RW, et al.: Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin’s disease. J Clin Oncol 2001, 19:736–741.PubMedGoogle Scholar
  16. 16.
    Kaplan H: Hodgkin’s Disease. Cambridge, MA: Harvard University Press; 1980.Google Scholar
  17. 17.
    Zittoun R, Audebert A, Hoerni B, et al.: Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 1985, 3:207–214.PubMedGoogle Scholar
  18. 18.
    Bonfante V, Viviani S, Devizz IL, et al.: Ten-year experience with ABVD plus radiotherapy: subtotal nodal (STNI) vs involved-field (IFRT) in early stage Hodgkin’s disease [abstract]. Proc ASCO 2001, 20:281a.Google Scholar
  19. 19.
    Ferme C, Eghbali H, Hagenbeek A, et al.: MOPP/ABV (M/A) hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II HD: comparison of three treatment modalities, preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients [abstract]. Blood 2000, 96:576a.Google Scholar
  20. 20.
    Engert A, Schiller P, Pfistner B, et al.: Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP/ABVD in patients with intermediate-stage HD [abstract]. Blood 2001, 98:768a.Google Scholar
  21. 21.
    Biti G, Cellai E, Magrini SM, et al.: Second solid tumors and leukemia after treatment for Hodgkin’s disease: an analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Physics 1994, 29:25–31.Google Scholar
  22. 22.
    Henry-Amar M: Second cancer after the treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s disease. Ann Oncol 1992, 3:117–128.PubMedGoogle Scholar
  23. 23.
    Swerdlow A, Douglas A, Hudson G, et al.: Risk of second primary cancers after Hodgkin’s disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Invertigation. BJM 1992, 304:1137–1148.Google Scholar
  24. 24.
    Kaplan H, Rosenberg S: The treatment of Hodgkin’s disease. Med Clin North Am 1966, 50:1591–1610.PubMedGoogle Scholar
  25. 25.
    Yahalom J, Mauch P: The involved-field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 2002, 13(suppl 1):79–83. Outlines the anatomic borders of involved-field RT in different common sites that reflect the consensus of several experts in the field.PubMedGoogle Scholar
  26. 26.
    Loeffler M, Diehl V, Pfreundschuh M, et al.: Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin’s disease. J Clin Oncol 1997, 15:2275–2287.PubMedGoogle Scholar
  27. 27.
    Salloum E, Doria R, Schubert W, et al.: Second solid tumors in patients with Hodgkin’s disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol 1996, 14:2435–2443.PubMedGoogle Scholar
  28. 28.
    Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993, 70:1949–1955.CrossRefGoogle Scholar
  29. 29.
    Bhatia S, Robison LL, Oberlin O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996, 334:745–751.PubMedCrossRefGoogle Scholar
  30. 30.
    Hoppe RT: Hodgkin’s disease: the role of radiation therapy in advanced disease. Ann Oncol 1996,4 (suppl):99–103.Google Scholar
  31. 31.
    Longo DL: The case against the routine use of radiation therapy in advanced-stage Hodgkin’s disease. Cancer Invest 1996, 14:353–360.PubMedGoogle Scholar
  32. 32.
    Prosnitz LR, Wu JJ, Yahalom J: The case for adjuvant radiation therapy in advanced Hodgkin’s disease. Cancer Invest 1996, 14:361–370.PubMedGoogle Scholar
  33. 33.
    Loeffler M, Brosteanu O, Hasenclever D, et al.: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease. International Database on Hodgkin’s Disease Overview Study Group. J Clin Oncol 1998, 16:818–829. Data from meta-analysis of small randomized studies addressing the role of adjuvant RT in advanced-stage disease and the substitution of RT with additional chemotherapy.PubMedGoogle Scholar
  34. 34.
    Mauch P: What is the role for adjuvant radiation therapy in advanced Hodgkin’s disease? [editorial; comment]. J Clin Oncol 1998, 16:815–817.PubMedGoogle Scholar
  35. 35.
    Young R, Canellos G, Chabner B, et al.: Patterns of relapse in advanced Hodgkin’s disease treated with combination chemotherapy. Cancer 1978, 42:1001–1007.PubMedCrossRefGoogle Scholar
  36. 36.
    Frei ED, Luce JK, Gamble JF, et al.: Combination chemotherapy in advanced Hodgkin’s disease: induction and maintenance of remission. Ann Intern Med 1973, 79:376–382.PubMedGoogle Scholar
  37. 37.
    Yahalom J, Ryu J, Straus DJ, et al.: Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin’s disease treated with alternating chemotherapy combinations. J Clin Oncol 1991, 9:2193–2201.PubMedGoogle Scholar
  38. 38.
    Fabian C, Mansfield C, Dahlberg S, et al.: Low-dose involved field radiation after chemotherapy in advanced Hodgkin’s disease. Ann Intern Med 1994, 120:903–912.PubMedGoogle Scholar
  39. 39.
    Pezner RD, Lipsett JA, Vora N, et al.: Radical radiotherapy as salvage treatment for relapse of Hodgkin’s disease initially treated by chemotherapy alone: prognostic significance of the disease-free interval. Int J Radiat Oncol Biol Physics 1994, 30:965–970.Google Scholar
  40. 40.
    Wirth A, Chao M, Corry J, et al.: Mantle irridation alonge for clinical stage I-II Hodgkin’s disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999, 17:230–240.PubMedGoogle Scholar
  41. 41.
    Brizel DM, Winer EP, Prosnitz LR, et al.: Improved survival in advanced Hodgkin’s disease with the use of combined modality therapy. Int J Radiat Oncol Biol Physics 1990, 19:535–542.Google Scholar
  42. 42.
    Diehl V, Loeffler M, Pfreundschuh M, et al.: Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin’s disease. German Hodgkins’ Study Group (GHSG). Ann Oncol 1995, 6:901–910.PubMedGoogle Scholar
  43. 43.
    Weiner MA, Leventhal B, Brecher ML, et al.: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin’s disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997, 15:2769–2779.PubMedGoogle Scholar
  44. 44.
    Raemaekers JMM, Aleman B, Henry-Amar M: Involved field irradiation (IFRT) does not improve outcome in patients with stage III/IV Hodgkin’s lymphoma (HL) in complete remission after MOPP/ABV (M/A): results of the randomised EORTC trial 20884 [abstract]. Blood 2001, 98:768a.Google Scholar
  45. 45.
    Horning SJ, Williams J, Bartlett NL, et al.: Assessment of the Stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin’s disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000, 18:972–980.PubMedGoogle Scholar
  46. 46.
    Horning SJ, Hoppe RT, Breslin S, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630–637. Mature data on a new concept and regimen for treating bulky and advanced-stage patients.PubMedCrossRefGoogle Scholar
  47. 47.
    Raemaekers J, Burgers M, Henry-Amar M, et al.: Patients with stage III/IV Hodgkin’s disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie. Ann Oncol 1997, 8(suppl 1):111–114.PubMedCrossRefGoogle Scholar
  48. 48.
    Prosnitz LR: Hodgkin’s disease: the right dose [editorial; comment]. Int J Radiat Oncol Biol Physics 1990, 19:803–804.Google Scholar
  49. 49.
    Maity A, Goldwein JW, Lange B, et al.: Comparison of highdose and low-dose radiation with and without chemotherapy for children with Hodgkin’s disease: an analysis of the experience at the Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania. J Clin Oncol 1992, 10:929–935.PubMedGoogle Scholar
  50. 50.
    Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med 1998, 339:1506–1514.PubMedCrossRefGoogle Scholar
  51. 51.
    Diehl V, Franklin J, Hasenclever D, et al.: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1998, 16:3810–3821.PubMedGoogle Scholar
  52. 52.
    Healey E, Tarbell N, Kalish L, et al.: Prognostic factors for patients with Hodgkin’s disease in first relapse. Cancer 1993, 71:2613–2620.PubMedCrossRefGoogle Scholar
  53. 53.
    Roach Md, Brophy N, Cox R, et al.: Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin’s disease. J Clin Oncol 1990, 8:623–629.PubMedGoogle Scholar
  54. 54.
    Santoro A, Viviani S, Villarreal CJ, et al.: Salvage chemotherapy in Hodgkin’s disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986, 70:343–348.PubMedGoogle Scholar
  55. 55.
    Bonfante V, Santoro A, Viviani S, et al.: Outcome of patients with Hodgkin’s disease failing after primary MOPP-ABVD. J Clin Oncol 1997, 15:528–534.PubMedGoogle Scholar
  56. 56.
    Longo DL, Duffey PL, Young RC, et al.: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin’s disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992, 10:210–218.PubMedGoogle Scholar
  57. 57.
    Yahalom J: Management of refractory and relapsed Hodgkin’s disease. Semin Radiat Oncol 1996, 6:210–224.PubMedCrossRefGoogle Scholar
  58. 58.
    Roach Md, Kapp DS, Rosenberg SA, et al.: Radiotherapy with curative intent: an option in selected patients relapsing after chemotherapy for advanced Hodgkin’s disease. J Clin Oncol 1987, 5:550–555.PubMedGoogle Scholar
  59. 59.
    Wirth A, Corry J, Laidlaw C, et al.: Salvage radiotherapy for Hodgkin’s disease following chemotherapy failure. Int J Radiat Oncol Biol Physics 1997, 39:599–607.CrossRefGoogle Scholar
  60. 60.
    Yahalom J: Integrating radiotherapy into bone marrow transplantation programs for Hodgkin’s disease [editorial; comment]. Int J Radiat Oncol Biol Physics 1995, 33:525–528.CrossRefGoogle Scholar
  61. 61.
    Yahalom J: Do not miss a second (and possibly last) chance to cure Hodgkin’s disease [editorial; comment]. Int J Radiat Oncol Biol Physics 1997, 39:595–597.CrossRefGoogle Scholar
  62. 62.
    Yahalom J, Gulati SC, Toia M, et al.: Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin’s disease. J Clin Oncol 1993, 11:1062–1070.PubMedGoogle Scholar
  63. 63.
    Poen JC, Hoppe RT, Horning SJ: High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin’s disease: the impact of involved field radiotherapy on patterns of failure and survival. Int J Radiat Oncol Biol Physics 1996, 36:3–12.CrossRefGoogle Scholar
  64. 64.
    Anderson JE, Litzow MR, Appelbaum FR, et al.: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin’s disease: the 21-year Seattle experience. J Clin Oncol 1993, 11:2342–2350.PubMedGoogle Scholar
  65. 65.
    Pezner RD, Nademanee A, Niland JC, et al.: Involved field radiation therapy for Hodgkin’s disease autologous bone marrow transplantation regimens. Radiother Oncol 1995, 34:23–29.PubMedCrossRefGoogle Scholar
  66. 66.
    Mundt AJ, Sibley G, Williams S, et al.: Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin’s disease. Int J Radiat Oncol Biol Physics 1995, 33:261–270.CrossRefGoogle Scholar
  67. 67.
    Jones RJ, Piantadosi S, Mann RB, et al.: High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 1990, 8:527–537.PubMedGoogle Scholar
  68. 68.
    Gianni AM, Siena S, Bregni M, et al.: Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin’s disease. Ann Oncol 1991, 2:645–653.PubMedGoogle Scholar
  69. 69.
    Phillips GL, Wolff SN, Herzig RH, et al.: Treatment of progressive Hodgkin’s disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989, 73:2086–2092.PubMedGoogle Scholar
  70. 70.
    McMillan A, Goldstone A: What is the value of autologous bone marrow transplantation in the treatment of relapsed or resistant Hodgkin’s disease? Leuk Res 1991, 15:237–243.PubMedCrossRefGoogle Scholar
  71. 71.
    Petersen FB, Appelbaum FR, Hill R, et al.: Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 1990, 8:638–647.PubMedGoogle Scholar
  72. 72.
    Mauch P, Tarbell N, Skarin A, et al.: Wide-field radiation therapy alone or with chemotherapy for Hodgkin’s disease in relapse from combination chemotherapy. J Clin Oncol 1987, 5:544–549.PubMedGoogle Scholar
  73. 73.
    Reece DE, Barnett MJ, Connors JM, et al.: Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin’s disease. J Clin Oncol 1991, 9:1871–1879.PubMedGoogle Scholar
  74. 74.
    Gribben JG, Linch DC, Singer CR, et al.: Successful treatment of refractory Hodgkin’s disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989, 73:340–344.PubMedGoogle Scholar
  75. 75.
    Moskowitz CH, Nimer SD, Zelenetz AD, et al.: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin’s disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616–623. A unique combined-modality approach to salvage of refractory and relapsed patients with very favorable results.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Joachim Yahalom
    • 1
  1. 1.Department of Radiation Oncology, Memorial Sloan-Kettering Cancer CenterWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations